PharmiWeb1h
Abbott Initiates New Intravascular Lithotripsy Clinical Trial to Improve Outcomes in Patients with Coronary Artery Disease
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its Coronary Intravascular Lithotripsy (IVL) System to ...
Medical Dialogues3h
Abbott begins new Intravascular Lithotripsy trial to improve outcomes in Coronary Artery Disease patients
Abbott has announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) ...
MassDevice22h
Abbott is making an IVL play with FDA IDE nod
Abbott (NYSE: ABT) received FDA investigational device exemption (IDE) approval for its coronary intravascular lithotripsy ...
Crain's Chicago Business19h
Abbott gets green light for clinical trials of new heart treatment system
Johnson & Johnson and Boston Scientific have also recently made moves to sell their own coronary intravascular lithotripsy ...